Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

GPR55 Antikörper (2nd Extracellular Loop)

Der Kaninchen Polyklonal anti-GPR55 Antikörper (ABIN7886262) detektiert spezifisch GPR55 in WB und FACS. Dieser Antikörper reagiert spezifisch mit Proben aus Human.
Produktnummer ABIN7886262
1.184,62 €
Zzgl. Versandkosten 20,00 € und MwSt
Lieferung nach: Deutschland
Lieferung in 8 bis 9 Werktagen

Kurzübersicht für GPR55 Antikörper (2nd Extracellular Loop) (ABIN7886262)

Target

Alle GPR55 Antikörper anzeigen
GPR55 (G Protein-Coupled Receptor 55 (GPR55))

Reaktivität

  • 47
  • 12
  • 8
  • 3
  • 3
  • 1
Human

Wirt

  • 51
Kaninchen

Klonalität

  • 51
Polyklonal

Konjugat

  • 21
  • 3
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser GPR55 Antikörper ist unkonjugiert

Applikation

  • 32
  • 21
  • 10
  • 8
  • 5
  • 2
  • 1
Western Blotting (WB), Flow Cytometry (FACS)
  • Bindungsspezifität

    • 16
    • 4
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    2nd Extracellular Loop, AA 160-174

    Verwendungszweck

    A Rabbit Polyclonal Antibody to GPR55

    Kreuzreaktivität (Details)

    The antibody will not recognize the protein from rat or mouse samples.

    Homologie

    Human only

    Produktmerkmale

    Anti-Human GPR55 (extracellular) Antibody (ABIN7043163, ABIN7044200 and ABIN7044201) is a highly specific antibody directed against an epitope of the human protein. The antibody can be used in western blot and live cell flow cytometry applications. It has been designed to recognize GPR55 from human samples only.

    Aufreinigung

    Affinity purified on immobilized antigen.

    Immunogen

    Peptide (C)HGKVEKYMSFHNMSD, corresponding to amino acid residues 160-174 of human GPR55

    Isotyp

    IgG
  • Applikationshinweise

    WB: 1:200-1:1000

    FC: 2.5 μg per reaction

    ICC: The optimal concentration should be determined by the user

    IHC: The optimal concentration should be determined by the user

    IP: The optimal concentration should be determined by the user

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

    Konzentration

    0.8 mg/mL

    Buffer

    PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C
  • Target

    GPR55 (G Protein-Coupled Receptor 55 (GPR55))

    Andere Bezeichnung

    GPR55

    Hintergrund

    Synonyms: G-protein coupled receptor 55

    Description: GPR55 is an endocannabinoid receptor that belongs to group δ of the rhodopsin-like (class A) receptors. Like all other G-protein coupled receptors, it consists of seven trans-membrane helixes, intracellular C-terminal domain and extracellular N-terminal extension1.The other known cannabinoid receptors, CB1 and CB2 share low homology with GPR55 and have different ligand specificity and different downstream activated cascade. Thus, GPR55 consists on its own a class of cannabinoid receptor2.GPR55 is highly expressed in the striatum and binds a wide range of ligands, among which are endocannabinoids: Anadanine and 2-Arachidonoyl Glycerol, and phytocannabinoids: Tetrahydrocannabinol (THC), abnormal cannabinoid (CBD) and cannabidiol3. Following ligand binding, GPR55 couples to Gα12,13 proteins, which eventually lead to increased intracellular Ca2+ levels2.The endocannabinoid system has a tremendous potential for experimental and clinical research, based on their evolutionary conservation and role in fundamental physiological and pathological processes, including pain modulation, immune function, neuroprotection, cancer, cardiovascular diseases, fertility and appetite4. Clinical studies using cannabinoid receptor agonists and antagonists have suggested their possible use in modulating acute and/or chronic diseases such as hypertension, glaucoma, emesis, anxiety, depression, gastrointestinal and hepatic disorders, ulcerative colitis and neuropathic and inflammatory pain5.

    Gen-ID

    9290

    NCBI Accession

    NM_005683

    UniProt

    Q9Y2T6
Sie sind hier:
Chat with us!